(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 January 2010 (28.01.2010)

PCT

(10) International Publication Number
WO 2010/011096 A3

(51) **International Patent Classification**:
C07K 19/00 (2006.01)

(21) **International Application Number**:
PCT/KR2009/004114

(22) **International Filing Date**:
23 July 2009 (23.07.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
10-2008-0071766 23 July 2008 (23.07.2008) KR

(71) **Applicant** *(for all designated States except US)*: **HANMI PHARMACEUTICAL CO., LTD.** [KR/KR]; 893-5 Hajeo-ri, Paltan-myeon, Hwaseong-si, Gyeonggi-do 445-813 (KR).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **SONG, Dae Hae** [KR/KR]; 307-2403 Samsungsan Apt., Sillim 10-dong, Gwanak-gu, Seoul 151-704 (KR). **SHIN, Jae Hee** [KR/KR]; 318-1905 Woobang Apt., Jeongja 2-dong, Jangan-gu, Suwon-si, Gyeonggi-do 440-302 (KR). **LEE, Mi Ji** [KR/KR]; 101-906 Daemyeong Apt., Yeonsu 1-dong, Yeonsu-gu, Incheon 406-111 (KR). **HONG, Sung Hee** [KR/KR]; 845-1002 Byeokjeokgol 8-danji, Yeongtong-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do 443-470 (KR). **KWON, Se Chang** [KR/KR]; 10-1204 Keukdong Apt., Gwangjang-dong, Gwangjin-gu, Seoul 143-751 (KR). **LEE, Gwan Sun** [KR/KR]; 3-404 Wuchang Apt., Ogeum-dong, Songpa-gu, Seoul 138-739 (KR).

(74) **Agent**: **SON, Min**; Hanol Law Offices, International IP Group, 6th Floor, City Air Tower, 159-9 Samseong-dong, Gangnam-gu Seoul 135-973 (KR).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

(88) **Date of publication of the international search report**:
27 May 2010

(54) **Title**: A POLYPEPTIDE COMPLEX COMPRISING NON-PEPTIDYL POLYMER HAVING THREE FUNCTIONAL ENDS

[Fig. 1]



(57) **Abstract**: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends(3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.

WO 2010/011096 A3